| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
4-Oxo-4-HPR targets tubulin as an inhibitor of tubulin polymerization. By inhibiting tubulin polymerization, it disrupts microtubule dynamics, which is essential for mitotic spindle formation during cell division. This leads to G2-M cell cycle arrest and apoptosis. As a metabolite of fenretinide, it may also interact with retinoic acid receptors or other targets, though its primary mechanism appears to be through tubulin inhibition.
|
|---|---|
| ln Vitro |
In vitro, 4-oxo-4-HPR induces cell growth inhibition in ovarian, breast, and neuroblastoma cell lines. It is an inhibitor of tubulin polymerization, inducing marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. The compound is able to inhibit 4-HPR-resistant cell growth and to act in cells that are resistant to fenretinide. Its in vitro activity has been confirmed in various cancer cell lines.
|
| ln Vivo |
In vivo, 4-oxo-4-HPR is a metabolite of fenretinide formed in the body. Fenretinide is a synthetic retinoid that has been studied for cancer prevention and treatment. The metabolite 4-oxo-4-HPR contributes to the overall pharmacological effects of fenretinide. Its ability to inhibit tubulin polymerization and induce apoptosis suggests potential anticancer activity in vivo. However, specific in vivo efficacy data are limited in publicly available sources.
|
| Enzyme Assay |
In non-cell-based biochemical assays, 4-oxo-4-HPR's inhibition of tubulin polymerization is evaluated using spectrophotometric methods. Purified tubulin is incubated with varying concentrations of 4-oxo-4-HPR, and the polymerization of tubulin into microtubules is monitored by measuring turbidity at 340 nm. The compound's IC50 for inhibition of tubulin polymerization is determined from inhibition curves. These assays confirm the compound's mechanism of action as a tubulin polymerization inhibitor.
|
| Cell Assay |
In vitro cellular assays for 4-oxo-4-HPR involve testing its effects on cultured cancer cells. Ovarian, breast, and neuroblastoma cell lines are treated with varying concentrations of 4-oxo-4-HPR. Cell viability, proliferation, and apoptosis are assessed using assays such as MTT, BrdU incorporation, and Annexin V staining. Cell cycle analysis is performed using flow cytometry to determine the percentage of cells arrested in G2-M phase. These assays have demonstrated the compound's ability to inhibit cell growth and induce apoptosis.
|
| Animal Protocol |
In vivo animal studies for 4-oxo-4-HPR have not been extensively reported, as the compound is a metabolite rather than a therapeutic agent. When studied, it is typically administered to animals to assess its pharmacokinetics, metabolism, and antitumor activity. Fenretinide is administered orally or intraperitoneally, and the formation of 4-oxo-4-HPR is measured in plasma and tissues. The compound's effects are compared to those of fenretinide.
|
| ADME/Pharmacokinetics |
4-Oxo-4-HPR has a molecular weight of 405.5 and a molecular formula of C26H31NO3. It is a metabolite of fenretinide (4-HPR). As a retinoid metabolite, it is expected to be lipophilic and to distribute to various tissues. Detailed pharmacokinetic parameters such as half-life, bioavailability, and clearance are similar to those of fenretinide and are available from fenretinide pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
As a research compound and metabolite, 4-oxo-4-HPR is not intended for human use. Comprehensive toxicology studies have not been extensively published, but the compound is generally considered safe for laboratory use. It should be handled with appropriate safety precautions, including the use of personal protective equipment. Its safety profile is consistent with that of other retinoid metabolites.
|
| Additional Infomation |
4-Oxo-4-HPR (4-Oxofenretinide) is a metabolite of fenretinide (4-HPR). It is also known as 4-oxo-N-(4-hydroxyphenyl)retinamide, 4-keto-4-HPR, and 3-keto fenretinide. It is an inhibitor of tubulin polymerization, inducing marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. It induces cell growth inhibition in ovarian, breast, and neuroblastoma cell lines. 4-Oxo-4-HPR is a research compound and is not an approved drug.
|
| Molecular Formula |
C26H31NO3
|
|---|---|
| Molecular Weight |
405.53
|
| Exact Mass |
405.23
|
| CAS # |
865536-65-8
|
| PubChem CID |
11258242
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.131g/cm3
|
| Boiling Point |
641.8ºC at 760 mmHg
|
| Flash Point |
341.9ºC
|
| Index of Refraction |
1.615
|
| LogP |
6.114
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
800
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(/C1=C(C)C(=O)CCC1(C)C)=C\C(\C)=C\C=C\C(\C)=C\C(=O)NC1C=CC(O)=CC=1
|
| InChi Key |
NZVOGZATHCUFRC-KFJFTADJSA-N
|
| InChi Code |
InChI=1S/C26H31NO3/c1-18(9-14-23-20(3)24(29)15-16-26(23,4)5)7-6-8-19(2)17-25(30)27-21-10-12-22(28)13-11-21/h6-14,17,28H,15-16H2,1-5H3,(H,27,30)/b8-6+,14-9+,18-7+,19-17+
|
| Chemical Name |
(2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenamide
|
| Synonyms |
4-Oxo-4-HPR 4Oxo4HPR4 Oxo 4 HPR 4-Oxo Fenretinide 4-Keto-4-HPR3-Keto fenretinide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4659 mL | 12.3295 mL | 24.6591 mL | |
| 5 mM | 0.4932 mL | 2.4659 mL | 4.9318 mL | |
| 10 mM | 0.2466 mL | 1.2330 mL | 2.4659 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
